Anti-DLL3 antibody drug conjugates
US9968687B2 · kind B2 · utility
2Cited by
51References
59Claims
0Family size
Assignees
Inventors
Key dates
| Filing date | Feb 21, 2014 |
| Grant date | May 15, 2018 |
| Priority date | — |
| Expiry date | May 12, 2034 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2317/92
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Provided are novel antibody drug conjugates (ADCs), and methods of using such ADCs to treat proliferative disorders.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.